A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis
Background : Multiple immunologic abnormalities such as impaired T-cell function, elevated serum IgE level, and increased interleukin 4 production have been demonstrated in patients with atopic dermatitis. Objective : As part of a 12-week, multicenter, double-blind, placebo-controlled clinical trial...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 1994-04, Vol.30 (4), p.597-602 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 602 |
|---|---|
| container_issue | 4 |
| container_start_page | 597 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 30 |
| creator | Stiller, Matthew J. Shupack, Jerome L. Kenny, Clare Jondreau, Lorrie Cohen, David E. Soter, Nicholas A. |
| description | Background
: Multiple immunologic abnormalities such as impaired T-cell function, elevated serum IgE level, and increased interleukin 4 production have been demonstrated in patients with atopic dermatitis.
Objective
: As part of a 12-week, multicenter, double-blind, placebo-controlled clinical trial, we evaluated the safety and efficacy of thymopentin (Timunox) as an adjunctive treatment in patients with severe atopic dermatitis.
Methods
: Thirty-nine patients at least 2 years old with severe atopic dermatitis on a minimum of 20% of their cutaneous surface area were randomly selected to receive either thrice-weekly subcutaneous injections of thymopentin, 50 mg, or placebo. Use of triamcinolone 0.1% or hydrocortisone 1.0% cream and oral antihistamines were permitted during this trial.
Results
: After 12 weeks, thymopentin-treated patients had significantly greater improvement than those receiving placebo. No thymopentin-related adverse events occurred.
Conclusion
: Thymopentin may be a safe effective adjunct to therapy in patients with severe atopic dermatitis. |
| doi_str_mv | 10.1016/S0190-9622(94)70068-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76439282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962294700680</els_id><sourcerecordid>76439282</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-b591083fc6c81dc0e1f17fc0009a43b0818619448f48bafc7b2ec8690d5f12b73</originalsourceid><addsrcrecordid>eNqFkc-OFCEQh4nRrLOrj7AJB2PcxFbo7mngtNls_Jds4kE9E7ooIhu6GYGeZN7DB5bemczVCxy-r6DqV4Rcc_aBMz58_MG4Yo0a2vad6m8EY4Ns2DOy4UyJZhBSPCebs_KSXOb8yBhTfScuyIXkWyHksCF_76iNyxiwGYOf7Xu6CwZwjA3EuaQYAloKlXgwgZbk1zNS3JuwmIK0_EaajcNyoGa2FJ2rIhxodBUdprjDufiZmlwxNfZxmaH4fa1LaMpUIV1piTsP1GKaTPHF51fkhTMh4-vTfUV-ff708_5r8_D9y7f7u4cGOqlKM24VZ7JzMIDkFhhyx4WDdUrTdyOTXA5c9b10vRyNAzG2CHJQzG4db0fRXZG3x3d3Kf5ZMBc9-QwYgpkxLlmLoe9UK9sqbo8ipJhzQqd3yU8mHTRnet2GftqGXqPWqtdP29Cs1l2fPljGCe256hR_5W9O3OQasEtmBp_PWs_W-VTVbo8a1jD2HpPO4HEGtD4hFG2j_08j_wDC6qkb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76439282</pqid></control><display><type>article</type><title>A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Stiller, Matthew J. ; Shupack, Jerome L. ; Kenny, Clare ; Jondreau, Lorrie ; Cohen, David E. ; Soter, Nicholas A.</creator><creatorcontrib>Stiller, Matthew J. ; Shupack, Jerome L. ; Kenny, Clare ; Jondreau, Lorrie ; Cohen, David E. ; Soter, Nicholas A.</creatorcontrib><description>Background
: Multiple immunologic abnormalities such as impaired T-cell function, elevated serum IgE level, and increased interleukin 4 production have been demonstrated in patients with atopic dermatitis.
Objective
: As part of a 12-week, multicenter, double-blind, placebo-controlled clinical trial, we evaluated the safety and efficacy of thymopentin (Timunox) as an adjunctive treatment in patients with severe atopic dermatitis.
Methods
: Thirty-nine patients at least 2 years old with severe atopic dermatitis on a minimum of 20% of their cutaneous surface area were randomly selected to receive either thrice-weekly subcutaneous injections of thymopentin, 50 mg, or placebo. Use of triamcinolone 0.1% or hydrocortisone 1.0% cream and oral antihistamines were permitted during this trial.
Results
: After 12 weeks, thymopentin-treated patients had significantly greater improvement than those receiving placebo. No thymopentin-related adverse events occurred.
Conclusion
: Thymopentin may be a safe effective adjunct to therapy in patients with severe atopic dermatitis.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/S0190-9622(94)70068-0</identifier><identifier>PMID: 8157786</identifier><identifier>CODEN: JAADDB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Child ; Dermatitis, Atopic - drug therapy ; Double-Blind Method ; Female ; Humans ; Injections, Subcutaneous ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Severity of Illness Index ; Skin, nail, hair, dermoskeleton ; Thymopentin - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Journal of the American Academy of Dermatology, 1994-04, Vol.30 (4), p.597-602</ispartof><rights>1994 American Academy of Dermatology, Inc.</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-b591083fc6c81dc0e1f17fc0009a43b0818619448f48bafc7b2ec8690d5f12b73</citedby><cites>FETCH-LOGICAL-c389t-b591083fc6c81dc0e1f17fc0009a43b0818619448f48bafc7b2ec8690d5f12b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962294700680$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4010839$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8157786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stiller, Matthew J.</creatorcontrib><creatorcontrib>Shupack, Jerome L.</creatorcontrib><creatorcontrib>Kenny, Clare</creatorcontrib><creatorcontrib>Jondreau, Lorrie</creatorcontrib><creatorcontrib>Cohen, David E.</creatorcontrib><creatorcontrib>Soter, Nicholas A.</creatorcontrib><title>A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Background
: Multiple immunologic abnormalities such as impaired T-cell function, elevated serum IgE level, and increased interleukin 4 production have been demonstrated in patients with atopic dermatitis.
Objective
: As part of a 12-week, multicenter, double-blind, placebo-controlled clinical trial, we evaluated the safety and efficacy of thymopentin (Timunox) as an adjunctive treatment in patients with severe atopic dermatitis.
Methods
: Thirty-nine patients at least 2 years old with severe atopic dermatitis on a minimum of 20% of their cutaneous surface area were randomly selected to receive either thrice-weekly subcutaneous injections of thymopentin, 50 mg, or placebo. Use of triamcinolone 0.1% or hydrocortisone 1.0% cream and oral antihistamines were permitted during this trial.
Results
: After 12 weeks, thymopentin-treated patients had significantly greater improvement than those receiving placebo. No thymopentin-related adverse events occurred.
Conclusion
: Thymopentin may be a safe effective adjunct to therapy in patients with severe atopic dermatitis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Severity of Illness Index</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Thymopentin - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-OFCEQh4nRrLOrj7AJB2PcxFbo7mngtNls_Jds4kE9E7ooIhu6GYGeZN7DB5bemczVCxy-r6DqV4Rcc_aBMz58_MG4Yo0a2vad6m8EY4Ns2DOy4UyJZhBSPCebs_KSXOb8yBhTfScuyIXkWyHksCF_76iNyxiwGYOf7Xu6CwZwjA3EuaQYAloKlXgwgZbk1zNS3JuwmIK0_EaajcNyoGa2FJ2rIhxodBUdprjDufiZmlwxNfZxmaH4fa1LaMpUIV1piTsP1GKaTPHF51fkhTMh4-vTfUV-ff708_5r8_D9y7f7u4cGOqlKM24VZ7JzMIDkFhhyx4WDdUrTdyOTXA5c9b10vRyNAzG2CHJQzG4db0fRXZG3x3d3Kf5ZMBc9-QwYgpkxLlmLoe9UK9sqbo8ipJhzQqd3yU8mHTRnet2GftqGXqPWqtdP29Cs1l2fPljGCe256hR_5W9O3OQasEtmBp_PWs_W-VTVbo8a1jD2HpPO4HEGtD4hFG2j_08j_wDC6qkb</recordid><startdate>19940401</startdate><enddate>19940401</enddate><creator>Stiller, Matthew J.</creator><creator>Shupack, Jerome L.</creator><creator>Kenny, Clare</creator><creator>Jondreau, Lorrie</creator><creator>Cohen, David E.</creator><creator>Soter, Nicholas A.</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940401</creationdate><title>A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis</title><author>Stiller, Matthew J. ; Shupack, Jerome L. ; Kenny, Clare ; Jondreau, Lorrie ; Cohen, David E. ; Soter, Nicholas A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-b591083fc6c81dc0e1f17fc0009a43b0818619448f48bafc7b2ec8690d5f12b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Severity of Illness Index</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Thymopentin - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stiller, Matthew J.</creatorcontrib><creatorcontrib>Shupack, Jerome L.</creatorcontrib><creatorcontrib>Kenny, Clare</creatorcontrib><creatorcontrib>Jondreau, Lorrie</creatorcontrib><creatorcontrib>Cohen, David E.</creatorcontrib><creatorcontrib>Soter, Nicholas A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stiller, Matthew J.</au><au>Shupack, Jerome L.</au><au>Kenny, Clare</au><au>Jondreau, Lorrie</au><au>Cohen, David E.</au><au>Soter, Nicholas A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>1994-04-01</date><risdate>1994</risdate><volume>30</volume><issue>4</issue><spage>597</spage><epage>602</epage><pages>597-602</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><coden>JAADDB</coden><abstract>Background
: Multiple immunologic abnormalities such as impaired T-cell function, elevated serum IgE level, and increased interleukin 4 production have been demonstrated in patients with atopic dermatitis.
Objective
: As part of a 12-week, multicenter, double-blind, placebo-controlled clinical trial, we evaluated the safety and efficacy of thymopentin (Timunox) as an adjunctive treatment in patients with severe atopic dermatitis.
Methods
: Thirty-nine patients at least 2 years old with severe atopic dermatitis on a minimum of 20% of their cutaneous surface area were randomly selected to receive either thrice-weekly subcutaneous injections of thymopentin, 50 mg, or placebo. Use of triamcinolone 0.1% or hydrocortisone 1.0% cream and oral antihistamines were permitted during this trial.
Results
: After 12 weeks, thymopentin-treated patients had significantly greater improvement than those receiving placebo. No thymopentin-related adverse events occurred.
Conclusion
: Thymopentin may be a safe effective adjunct to therapy in patients with severe atopic dermatitis.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>8157786</pmid><doi>10.1016/S0190-9622(94)70068-0</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 1994-04, Vol.30 (4), p.597-602 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76439282 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Aged Biological and medical sciences Child Dermatitis, Atopic - drug therapy Double-Blind Method Female Humans Injections, Subcutaneous Male Medical sciences Middle Aged Pharmacology. Drug treatments Severity of Illness Index Skin, nail, hair, dermoskeleton Thymopentin - therapeutic use Time Factors Treatment Outcome |
| title | A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A05%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20double-blind,%20placebo-controlled%20clinical%20trial%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20thymopentin%20as%20an%20adjunctive%20treatment%20in%20atopic%20dermatitis&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Stiller,%20Matthew%20J.&rft.date=1994-04-01&rft.volume=30&rft.issue=4&rft.spage=597&rft.epage=602&rft.pages=597-602&rft.issn=0190-9622&rft.eissn=1097-6787&rft.coden=JAADDB&rft_id=info:doi/10.1016/S0190-9622(94)70068-0&rft_dat=%3Cproquest_cross%3E76439282%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76439282&rft_id=info:pmid/8157786&rft_els_id=S0190962294700680&rfr_iscdi=true |